Joseph S Zakrzewski's Insider Trades & SAST Disclosures
Joseph S Zakrzewski's most recent trade in AN2 Therapeutics Inc was a trade of 10,523 Common Stock done . Disclosure was reported to the exchange on April 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Joseph S Zakrzewski.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AN2 Therapeutics Inc | Joseph S. Zakrzewski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2025 | 10,523 | 145,538 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Joseph S. Zakrzewski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 9,816 | 135,015 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Joseph Zakrzewski S. | Director | Purchase of securities on an exchange or from another person at price $ 1.40 per share. | 27 Nov 2024 | 2,000 | 125,199 | - | 1.4 | 2,800 | Common Stock |
| AN2 Therapeutics Inc | Joseph S. Zakrzewski | Director | Purchase of securities on an exchange or from another person at price $ 1.00 per share. | 18 Nov 2024 | 20,000 | 118,199 | - | 1.0 | 19,996 | Common Stock |
| AN2 Therapeutics Inc | Joseph S. Zakrzewski | Director | Purchase of securities on an exchange or from another person at price $ 1.01 per share. | 18 Nov 2024 | 5,000 | 123,199 | - | 1.0 | 5,050 | Common Stock |
| AN2 Therapeutics Inc | Joseph S. Zakrzewski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2024 | 64,503 | 64,503 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | S. Joseph Zakrzewski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 14,150 | 0 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | Joseph S. Zakrzewski | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.69 per share. | 06 Feb 2024 | 14,150 | 227,439 | - | 1.7 | 23,914 | Common Stock |
| AN2 Therapeutics Inc | S. Joseph Zakrzewski | Director | Sale of securities on an exchange or to another person at price $ 19.11 per share. | 18 Jan 2024 | 100,000 | 405,880 | - | 19.1 | 1,911,410 | Common Stock |
| Cyteir Therapeutics Inc | Joseph S. Zakrzewski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 14,150 | 14,150 | - | - | Stock Option (Right to Buy) | |
| AN2 Therapeutics Inc | Joseph S. Zakrzewski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 10,362 | 10,362 | - | - | Stock Option (right to buy) | |
| Cyteir Therapeutics Inc | Joseph S. Zakrzewski | Director | Purchase of securities on an exchange or from another person at price $ 1.61 per share. | 12 May 2022 | 743 | 133,416 | - | 1.6 | 1,196 | Common Stock |
| Cyteir Therapeutics Inc | Joseph S. Zakrzewski | Director | Purchase of securities on an exchange or from another person at price $ 1.89 per share. | 10 May 2022 | 49,406 | 131,673 | - | 1.9 | 93,377 | Common Stock |
| Cyteir Therapeutics Inc | Joseph S. Zakrzewski | Director | Purchase of securities on an exchange or from another person at price $ 1.70 per share. | 10 May 2022 | 1,000 | 132,673 | - | 1.7 | 1,700 | Common Stock |
| AN2 Therapeutics Inc | Joseph S. Zakrzewski | Director | 29 Mar 2022 | 98,199 | 0 | - | - | Series A Convertible Preferred Stock | ||
| AN2 Therapeutics Inc | Joseph S. Zakrzewski | Director | 29 Mar 2022 | 98,199 | 98,199 | - | - | Common Stock | ||
| Sangamo Therapeutics Inc | Joseph S. Zakrzewski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Joseph S. Zakrzewski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 12,500 | 60,700 (0%) | 0% | 0 | Common Stock | |
| Cyteir Therapeutics Inc | Joseph S. Zakrzewski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 14,150 | 14,150 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | Joseph S. Zakrzewski | Director | Purchase of securities on an exchange or from another person at price $ 9.85 per share. | 23 Dec 2021 | 601 | 82,267 | - | 9.9 | 5,920 | Common Stock |
| Cyteir Therapeutics Inc | Joseph S. Zakrzewski | Director | Purchase of securities on an exchange or from another person at price $ 9.87 per share. | 23 Dec 2021 | 200 | 81,367 | - | 9.9 | 1,974 | Common Stock |
| Cyteir Therapeutics Inc | Joseph S. Zakrzewski | Director | Purchase of securities on an exchange or from another person at price $ 9.97 per share. | 23 Dec 2021 | 200 | 81,567 | - | 10.0 | 1,994 | Common Stock |
| Cyteir Therapeutics Inc | Joseph S. Zakrzewski | Director | Purchase of securities on an exchange or from another person at price $ 10.18 per share. | 23 Dec 2021 | 99 | 81,666 | - | 10.2 | 1,008 | Common Stock |
| Cyteir Therapeutics Inc | Joseph S. Zakrzewski | Director | Purchase of securities on an exchange or from another person at price $ 9.88 per share. | 17 Dec 2021 | 200 | 81,167 | - | 9.9 | 1,976 | Common Stock |
| Cyteir Therapeutics Inc | Joseph S. Zakrzewski | Director | Purchase of securities on an exchange or from another person at price $ 10.47 per share. | 15 Dec 2021 | 2,000 | 79,267 | - | 10.5 | 20,940 | Common Stock |
| Cyteir Therapeutics Inc | Joseph S. Zakrzewski | Director | Purchase of securities on an exchange or from another person at price $ 11.12 per share. | 15 Dec 2021 | 1,700 | 80,967 | - | 11.1 | 18,904 | Common Stock |
| Cyteir Therapeutics Inc | Joseph S. Zakrzewski | Director | 22 Jun 2021 | 200,000 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Cyteir Therapeutics Inc | Joseph S. Zakrzewski | Director | 22 Jun 2021 | 58,671 | 58,671 | - | - | Common Stock | ||
| Sangamo Therapeutics Inc | Joseph S. Zakrzewski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 16,400 | 16,400 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Joseph S. Zakrzewski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 8,200 | 48,200 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges